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Abstract
Type 2 diabetes continues to be a serious and highly prevalent public health 
problem worldwide. In 2019, the highest prevalence of diabetes in the world at 
12.2%, with its associated morbidity and mortality, was found in the Middle East 
and North Africa region. In addition to a genetic predisposition in its population, 
evidence suggests that obesity, physical inactivity, urbanization, and poor 
nutritional habits have contributed to the high prevalence of diabetes and 
prediabetes in the region. These risk factors have also led to an earlier onset of 
type 2 diabetes among children and adolescents, negatively affecting the 
productive years of the youth and their quality of life. Furthermore, efforts to 
control the rising prevalence of diabetes and its complications have been 
challenged and complicated by the political instability and armed conflict in some 
countries of the region and the recent coronavirus disease 2019. Broad strategies, 
coupled with targeted interventions at the regional, national, and community 
levels are needed to address and curb the spread of this public health crisis.
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The worldwide prevalence of diabetes mellitus continues to grow with no sign of 
reversal. Data from the World Health Organization (WHO) shows that diabetes rose 
80% in prevalence between 1980 and 2014[1], and the International Diabetes 
Federation (IDF) estimates that in 2019, 9.3% of the global adult population age 20-79 
years suffered from diabetes[2]. Compared to high income countries (HIC), this 
increase disproportionately affects low- and middle-income countries and adds a 
burden of excess morbidity, mortality, and health care costs[3]. Specifically, the Middle 
East and North Africa region (MENA) carried the highest prevalence of diabetes in 
2019 at 12.2% and is expected to witness a 96% increase in diabetes prevalence 
between 2019 and 2045, second only to the African region with a 143% projected rise
[4]. To compare, over the same time period, the prevalence in Europe and North 
America/Caribbean regions is expected to increase by 15% and 33%, respectively. 
Moreover, 44.7% of people with type 2 diabetes (T2D) in the MENA region are 
unaware of their condition[4].
Despite the heterogeneity within the MENA countries in terms of culture, income, 
population size, and sociopolitical stability[5,6], multiple common predisposing 
factors for diabetes have been implicated, including aging of the population, the 
change in lifestyle with reduction in physical activity, and increased consumption of 
calories and unhealthy food items, which have led to a rise in the prevalence of 
overweightness and obesity[2]. Genetic and epigenetic factors may also be 
contributing elements[7]; in a region that has a high rate of consanguinity[8], multiple 
gene loci that predispose to diabetes have been identified in the Eastern Mediterranean 
Region (EMR) population[9]. In addition to diabetes, prediabetes has been identified in 
a sizable proportion of the MENA population[2], out of whom a majority is expected 
to progress to diabetes over time[10].
This unrelenting diabetes epidemic was an important driving factor that spurred the 
2011 declaration of the United Nations general assembly, in which countries 
committed to work on national plans for preventing and controlling noncommu-
nicable diseases (NCD)[11]. In addition to the risk factors behind the worldwide rise in 
diabetes prevalence, other factors, specific to the MENA region, are contributing to the 
epidemic[12]. Measures to address the high numbers in the MENA area have been 
ineffective partly due to inadequate funding, insufficient commitment, political 
instability, and armed conflict in multiple countries[13,14].
This review aims at describing the current prevalence of diabetes and prediabetes in 
the MENA region, the contributing risk factors, common diabetes complications, and 
strategies that can help curb its spread and complications.
METHODOLOGY
We searched Medline (OVID electronic database Ovid MEDLINE(R) and Epub Ahead 
of Print, In-Process and Other Non-Indexed Citations and Daily 1946 to December 07, 
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2020) for studies reporting in 20 countries of the MENA region not only diabetes 
mellitus and cardiovascular diseases (CVDs), but also diabetic foot or amputation, 
diabetic nephropathies, diabetic retinopathy (DR), the prevalence of diabetes, and the 
prevalence of diabetes for the pediatric and adolescent age group. Each of the latter 
searches was exported into Endnote X9 Software, and the library was screened for 
relevant literature. The search did include the Medical Subject headings (MESH) for all 
the concepts except for countries in which keywords were added along to MESH to 
ensure a wider range of results. Only articles in the English language and with studies 
where specific complication prevalence was evaluated were selected for our paper. We 
limited the prevalence studies to publications within the last decade (2010-2020). For 
diabetes prevalence studies, we excluded hospital and clinic-based studies.
There has been no consensus on which countries define the MENA region. For our 
review, we have included the following 20 countries: Afghanistan, Algeria, Bahrain, 
Egypt, Iran, Iraq, Jordan, Kuwait, Lebanon, Libya, Morocco, Oman, Pakistan, 
Palestine, Qatar, Saudi Arabia, Syria, Tunisia, United Arab Emirates (UAE), and 
Yemen. These countries are commonly included in the definition of EMR (EMRO). 
Therefore, we included data from the WHO, which reports on EMRO, and IDF, which 
reports on MENA.
PREVALENCE OF T2D
Diagnostic criteria for diabetes
The diagnostic criteria for diabetes by the American Diabetes Association (ADA) 
include the following: hemoglobin A1c 6.5%, fasting plasma glucose 126 mg/dL (7.0 
mmol/L), oral glucose tolerance test with 2 h plasma glucose 200 mg/dL (11.1 
mmol/L), or casual plasma glucose 200 mg/dL (11.1 mmol/L) in the presence of 
hyperglycemic symptoms[15]. It is worth noting that the IDF follows the ADA criteria 
in the diagnosis of T2D[16]. On the other hand, the WHO defines diabetes as raised 
fasting glucose 126 mg/dL (7.0 mmol/L), history of diabetes, or using antidiabetic 
medication[17]. Unless stated otherwise, the studies included in the prevalence 
paragraph follow either ADA or WHO diagnostic criteria.
Prevalence
In 2019 and as previously stated, 9.3% of adults were living with diabetes worldwide, 
with a predicted rise to 10.2% and 10.9% by years 2030 and 2045, respectively. The 
highest age adjusted prevalence was reported in the MENA reaching 12.2%, where 1 in 
8 adults was living with diabetes[2]. The WHO provides periodic country-specific 
rates of diabetes compiled from various studies[17]. We used WHO data to rank 
MENA countries by diabetes prevalence between 2000 and 2014[17], as shown in 
Figure 1.
The highest age standardized diabetes prevalence in the MENA region in the year 
2000 was in Kuwait with a prevalence of 15.4%, and the lowest prevalence was 6.8% in 
Yemen. Between 2000 and 2014, all 20 countries of the MENA region discussed in this 
paper experienced an increase in prevalence while Kuwait kept its first ranking among 
these countries, for having the highest prevalence among them at 19.6% (Figure 1). 
Kuwait has already exceeded its projected prevalence of diabetes for 2030, which was 
anticipated to be 16.9%[18]. Another high-income country, Qatar, ranked second in 
prevalence among MENA countries, following Kuwait, both in 2000 and 2014 
(Figure 1). In Saudi Arabia, a cross-sectional study was conducted from 2007 to 2009 
and included 18034 individuals older than 30 years. It found the prevalence of diabetes 
was 25.4% (out of which 10.2% were previously undiagnosed), and it was significantly 
higher in urban compared to rural areas[19].
Moving to Pakistan, in 2017, a large-scale national study including 18856 adults 
(above 20 years of age), found that T2D prevalence was 16.9% (n = 3201), and diabetes 
was significantly associated with age[20]. In 2019, the age-adjusted comparative 
prevalence in Pakistan rose to 19.9%, and that country was ranked first among the 
MENA countries for having the highest number of people (19.4 million) living with 
diabetes[2]. To understand the trend in diabetes prevalence in Jordan, four surveys 
using the same diagnostic criteria (the WHO criteria) were conducted in the years 
1994, 2004, 2009, and 2017. Over the years, the age-adjusted prevalence increased from 
17.1% in 2004 to 23.7% in 2017. This steep increase was attributed not only to increased 
incidence, but also to other factors like aging of the population and better survival of 
individuals with diabetes. In addition, the percentage of previously diagnosed 
diabetes increased as well, accounting for 82.6% of all diabetes cases in 2017, indicating 
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Figure 1 Middle East and North Africa countries ranked by prevalence of type 2 diabetes in 2000 and 2014 (prevalence and confidence 
intervals are in %)[1]. CI: Confidence interval.
improved screening and diabetes awareness[21].
Moving to North Africa, and according to the WHO, the prevalence of diabetes in 
Egypt in 2014 was 17.9%, the third highest prevalence in the MENA region. In 2019, 
Egypt occupied the second highest rank among MENA countries with respect to 
number of adults living with diabetes, with almost 9 million cases[2]. However, within 
Egypt, the prevalence was much lower in rural areas compared to the national 
average. As an example, a community-based cross-sectional study conducted in Qena 
Governorate over 2 years (2013-2015) found that 811 out of 9303 had T2D (8.7%). It is 
worth noting that the majority of participants (n = 7701) were younger than 40 years of 
age, which likely contributed to the relatively low prevalence in this governorate[22].
In a neighboring country to Egypt, Tunisia, the most recent national cross-sectional 
survey we could identify was conducted in 2005 and involved 7700 adults, age 35 to 70 
years. It found that the prevalence of T2D, based on WHO criteria, was 15.5%. Again, 
within that study, the urban prevalence was twice as high as in rural areas (17.7% vs 
9.7%, respectively)[23].
As for Iran, a national survey conducted in 2011 found that the prevalence of 
diabetes (T1D and T2D combined) was 11.4%, and the annual incidence was estimated 
to be 1%[24]. Two large community-based cross-sectional studies yielded the 
following: in the Yazd area of central Iran, out of 2269 adults above 20 years, the crude 
prevalence of self-reported diabetes in 2014-2015 was 14.1%, and 1 out of every 5 
people over 40 years of age was living with diabetes[25]. In contrast, the Pars Cohort 
Study in Southern Iran conducted on 9264 adults aged 40-75 years, found a slightly 
lower prevalence of diabetes of 9.9% using self-report and fasting plasma glucose[26,
27]. In either case, the prevalence is increasing over time, as was shown in a 5 year 
study in the city of Ahvaz. Out of 593 participants above 20 years of age, the 
prevalence of diabetes was 15.2% in 2009 and increased to 20.9% in 2014[27]. In both 
Southern and Southwest areas of Iran, diabetes prevalence was positively correlated 
with low education level, body mass index (BMI), and age.
Moving to Lebanon, a cross-sectional national survey including adults above 25 
years of age found a prevalence of self-reported diabetes of 8.5%; the prevalence was 
higher among older age, obese, and less physically active groups[28]. A more recent 
community-based survey that was conducted in Beirut in 2014, found that the 
prevalence of diabetes, based on self-report, fasting glucose, or hemoglobin A1c, was 
18.0%. Similarly, increasing age and BMI were risk factors[29]. The higher prevalence 
reported in this study, compared to the previously mentioned one, can be attributed to 
the different diagnostic criteria of diabetes and the characteristics of the participants, 
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where they had a higher obesity rate and were residing in Beirut, the capital of 
Lebanon, unlike the first survey that included both an urban and a rural population. In 
2019, the IDF estimated the age adjusted comparative diabetes prevalence in Lebanon 
at 11.2%[2]. Other countries in the MENA region did not have recent or large 
community-based studies to estimate the prevalence of diabetes in the population. 
These countries (except for Morocco and Algeria) are more likely to have political 
instability and/or conflict (Libya, Iraq, Yemen, Afghanistan, Syria, Palestine, and 
Bahrain). The most recent community-based survey from Syria was conducted in 2006 
in the city of Aleppo and reported the total prevalence of T2D to be 15.6%, out of 
whom 5% were newly diagnosed, while the rest were self-reported cases. Like other 
studies, the prevalence was correlated with obesity and a positive family history[30]. 
In 2019, based on extrapolation from similar countries, the IDF stated that more than 1 
million adults were living with diabetes in Syria[2]. Unfortunately, Palestine, like 
Syria, lacks recent surveys and studies on a national level; however, the IDF estimated 
that the prevalence of diabetes in Palestine was 7% in 2017[31] and 9.5% in 2019[2].
Prevalence of diabetes by gender
The prevalence of diabetes was higher in women than men in several of the MENA 
countries (Table 1). Yet, some countries showed a higher prevalence in males 
compared to females, as is the case for Lebanon[28]. Gender differences may vary even 
within regions of the same country; for example, women in Central Iran[25] and the 
rural area of Kurdistan province[32] had a higher prevalence than men, whereas no 
significant differences in prevalence by genders was observed in the Southwest of Iran
[27].
Given that other global studies do not show a higher predisposition to diabetes 
among females, it is likely that it is the gender factor, and not the physiologic sex 
factor, that contributes to the risk. This is supported by the higher prevalence of 
obesity and sedentary lifestyle among women, as described in the risk factors section. 
The prevalence by gender is shown in Table 1 and Figure 2.
Urban vs rural
Studies mentioned previously for Egypt[21], Tunisia[22], and Lebanon[28,29] have 
shown a higher T2D prevalence in urban compared to rural areas. Similarly, a study 
including 9149 participants aged 7-80 years from Riyadh, the capital of Saudi Arabia, 
found that the prevalence of diabetes, based on the WHO definition, was 31.6%[33], 
which is higher than the overall reported national prevalence[17].
The higher urban compared to rural prevalence is not consistent across or within 
studies. For example, a national diabetes survey in Pakistan conducted in the years 
2016-2017 found a significantly higher prevalence in urban vs rural areas among males 
above 60 years of age and among females; however, younger males showed a higher 
prevalence in rural areas[34].
Similarly, the prevalence of diabetes in Iran was higher in rural compared to urban 
areas; it was noted that in the rural population of Kurdistan province, the prevalence 
of T2D in 2011-2017 was 19.6%. The prevalence was significantly associated with age 
and lower level of education. In this specific population, genetic polymorphisms were 
more common among rural populations, predisposing them to a higher risk of 
diabetes[32].
It is likely that the difference in prevalence in urban vs rural areas is attributed to 
different nutritional habits, activity level, and possibly a more health-promoting 
environment.
Unknown vs known diabetes
The rate of unknown or undiagnosed diabetes can be detected by population-based 
studies that collect blood samples and measure hemoglobin A1c or glucose levels. The 
proportion of undiagnosed diabetes in the MENA region was 44.7% in 2019[16]. In 
Kuwait, a cross-sectional survey in 2007 found that 23 subjects out of 120 diabetic 
adults were previously undiagnosed (19%)[35]. Similarly, in Pakistan, the rate of 
unknown diabetes was 27%[34].
In central Iran, undiagnosed diabetes was found to be more common in men (4%) 
than in women (3.7%), and it was significantly associated with older age; the 
prevalence of undiagnosed diabetes was 4.8 times higher in the age group 60-69 years 
compared to the youngest age group 20-29 years, indicating a higher level of diabetes 
unawareness in the older population[25]. In Beirut (Lebanon), 26 subjects out of 90 
were unaware that they had diabetes (29%)[29]. In Jordan, the percentage of newly 
diagnosed cases compared to all diabetic cases was 25.5% in 2004, and it dropped to 
17.4% in 2017[21]. In Qena, Egypt, around 35% of all the diabetes cases (both types) 
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Table 1 Gender specific prevalence of type 2 diabetes in % (CI) in 20 Middle East and North Africa countries in 2000 and 2014 as 
reported by the World Health Organization[1] and for Palestine[144]
2000 2014
Country
Men Women Men Women
Afghanistan 8.1 (5.3-11.5) 8.5 (5.7-11.9) 11.6 (6.4-18.2) 12.2 (6.8-18.8)
Algeria 8.6 (6.0-11.8) 9.2 (6.5-12.3) 12.3 (7.4-18.8) 12.6 (7.7-18.9)
Bahrain 10.6 (7.6-14.2) 9.9 (7.1-13.5) 12.0 (7.0-18.5) 10.6 (6.1-16.7)
Egypt 10.8 (7.5-14.7) 13.3 (9.6-17.5) 16.0 (10.0-23.6) 19.8 (12.9-28.2)
Iran 7.4 (5.5-9.4) 8.5 (6.4-10.7) 11.4 (7.2-17.2) 12.9 (8.4-18.8)
Iraq 11.5 (8.2-15.4) 12.4 (9.1-16.2) 17.2 (10.7-25.3) 17.5 (11.1-25.4)
Jordan 12.0 (8.8-15.9) 14.0 (10.5-18.0) 16.5 (10.5-24.0) 17.2 (11.3-24.6)
Kuwait 15.3 (11.2-20.3) 15.6 (11.4-20.4) 19.7 (12.8-28.1) 19.6 (12.9-27.7)
Lebanon 9.0 (5.7-13.1) 8.4 (5.3-12.2) 14.5 (8.7-21.8) 12.2 (7.4-18.5)
Libya 10.7 (7.9-14.1) 12.2 (9.1-15.8) 15.2 (9.5-22.5) 16.6 (10.7-23.8)
Morocco 9.0 (6.2-12.4) 9.2 (6.4-12.6} 14.0 (8.4-21.5} 13.4 (8.1-20.5}
Oman 10.2 (7.6-13.6) 9.9 (7.3-13.1) 14.3 (8.6-21.7) 12.3 (7.4-18.4)
Pakistan 9.1 (6.3-12.2) 9.0 (6.3-12.2) 12.6 (7.0-19.5) 12.1 (7.0-18.6)
Palestine 10.6 (7.8-14.0) 11.8 (8.9-15.2) 16.5 (10.3-24.3) 17.5 (11.4-24.9)
Qatar 13.7 (9.9-18.1) 14.2 (10.4-18.5) 18.9 (12.0-27.0) 18.8 (12.2-26.8)
Saudi Arabia 13.1 (9.8-17.1) 13.1 (9.8-17.0) 17.6 (11.5-25.4) 17.0 (11.1-24.4)
Syria 9.8 (7.0-13.2) 10.9 (8.1-14.2) 14.0 (8.5-21.0) 15.3 (9.6-22.4)
Tunisia 8.3 (6.0-11.1) 9.7 (7.2-12.7) 12.1 (7.4-18.3) 12.9 (7.9-19.0)
United Arab Emirates 11.8 (8.6-16.0) 12.4 (9.1-16.5) 15.0 (9.2-22.5) 15.4 (9.7-22.6)
Yemen 7.4 (4.5-11.3) 6.2 (3.6-9.4) 12.6 (6.7-20.6) 10.1 (5.3-17.0)
Figure 2 Prevalence of type 2 diabetes by gender in years 2000 and 2014 from the World Health Organization[1] and for Palestine[144].
were newly diagnosed[22], and Tunisia showed one of the highest rates of 
undiagnosed diabetes at 51.1%[23].
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PREDIABETES
The development of diabetes tends to be a gradual process with rising glucose levels 
from the normoglycemic range to the diabetic range. This process is driven by a 
combination of metabolic disorders that include both insulin resistance and a 
progressive decline in insulin secretion[10]; the term prediabetes has been used to 
characterize the intermediate state between normoglycemia and the glucose levels that 
define diabetes[2,15]. Patients with prediabetes comprise those with impaired fasting 
glucose (IFG) and/or impaired glucose tolerance (IGT)[15]. Like diabetes, patients 
with prediabetes are at an increased risk of cardiovascular events but to a lesser extent. 
Previous studies have suggested that up to 70% of patients with prediabetes will 
eventually progress to diabetes[10], however implementation of lifestyle changes or 
pharmacologic therapy may prevent or delay that progression[36]. It is estimated that 
25%-50% of patients with prediabetes may progress to diabetes within 5 years of 
diagnosis[37].
In addition to the high prevalence of diabetes, countries in the MENA region also 
suffer from a high prevalence of prediabetes. The IDF estimates that in 2019, the 
worldwide age adjusted comparative prevalence of IGT in adults aged 20-79 years was 
8.6%, with the European region being least affected at a prevalence of 4.4%, and the 
Western Pacific region having the highest prevalence at 10.4%[2]. The estimated 
MENA prevalence of IGT was intermediate at 9.2% and is projected to increase to 9.9% 
by 2045. Even though the projected prevalence goes up only by 0.7%, it translates into 
near doubling of the number from 35.5 million to 64.5 million adults with IGT mostly 
due to population growth.
Within the past 20 years, a relatively small number of studies have reported on the 
prevalence of prediabetes in the MENA countries, however there was a wide 
variability among them in the definition of prediabetes, the sample size and sampling 
technique, and the age group sampled (Table 2). Overall, there did not appear to be a 
major difference between gender subgroups. A relatively high prevalence of 
prediabetes was reported in Iraq[38], Saudi Arabia[19], the UAE[39], and Kuwait[40], 
ranging between 19.3% and 28.6%. An intermediate prevalence was found in the 
countries of Iran[41], Pakistan[34], and Qatar[42] with a prevalence ranging from 
13.8% to 14.6%. The countries of Yemen[43], Syria[30], Oman[44], and Tunisia[45] 
boasted a relatively low prevalence with a range of 4.6%-9.0%. A Lebanese study 
limited to the greater Beirut area reported an unusually high prevalence of prediabetes 
of 40.3%[29]; the way prediabetes was defined could have been a factor affecting the 
results, since either an elevated fasting glucose or a high A1c were acceptable 
parameters, while most of the other studies limited the prediabetes definition to IFG.
The values estimated by IDF for the prevalence of IGT in 2019 are overall lower 
compared to those reported for individual countries in the table, possibly because IDF 
limited their data collection to studies of IGT and excluded those that had also 
included isolated IFG in the definition of prediabetes. In addition, for the IDF data, 
only Algeria, Jordan, Oman, Pakistan, Saudi Arabia, Palestine, and the UAE had 
estimates based on oral glucose tolerance test. Diabetes prevalence for the remaining 
countries were extrapolated using values from countries deemed to be similar 
(geographic location, World Bank income group, ethnicity, language, and IDF region) 
and may be under-estimated[4].
RISK FACTORS
Multiple risk factors have been implicated in the increase in T2D prevalence. The 
change to a more sedentary lifestyle and the westernization of dietary habits with a 
shift to fast food and items rich in refined sugar and animal fat play a major role. 
Additional factors may also contribute to the rising prevalence, including cigarette and 
waterpipe smoking[46], pollution of the environment[47], and a high prevalence of 
hepatitis C in some countries (mainly Egypt and Pakistan)[48,49]. Moreover, there is 
evidence that people in lower socioeconomic groups are at increased risk of T2D[50].
Genetics
In addition to the well-known contributing effect of aging, sedentary lifestyle, 
unhealthy diets, and obesity in the development of diabetes, genetics also appear to 
play a role. A family history of diabetes in first degree relatives has long been known 
to increase the diabetes risk by up to 3-fold[51].
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Table 2 Prevalence of prediabetes (%) in some Middle East and North Africa countries
Prevalence of prediabetes % (95%CI)
Ref. Country, yr Age group (n)
Definition of 





≥ 18 yr (501) IFG: FPG 5.6-6.9 










Mansour et al[38] Iraq, 2011-2012 19-94 yr 
(5445)
IFG: FPG 5.7-6.9 









≥ 30 yr 
(18034)





Saadi et al[39] United Arab Emirates 
(Al-Ain), 2005-2006
> 18 yr 
(2455)
IFG: FPG 5.6-6.9 mmol/l 
or IGT
Simple random sample 19.7 22.8 22.8
Alkandari et al
[40]
Kuwait, 2014 18-69 yr 
(2561)
IFG: FPG 6.1-6.9 
mmol/L








Iran, 2011 25-70 yr 
(11867)










Basit et al[34] Pakistan, 2016-2017 ≥ 20 yr 
(10834)





Bener et al[42] Qatar, 2007-2008 > 20 yr 
(1117)









5.7 (2.8-8.6) 10.9 (7.1-14.7) 9.0 (6.0-12.0)
Albache et al[30] Syria (Aleppo), 2006 ≥ 25 yr (806) IFG: FPG 6.1-6.9 
mmol/L
Random sampling 10.4 (4.7-
21.0)
6.8 (2.9-15.1) 8.6 (3.8-18.1)
Al-Lawati et al
[44]
Oman, 2000 ≥ 20 yr 
(5838)




7.1 (6.2-8.1) 5.1 (4.4-6.0) 6.1 (5.5-6.8)
Bouguerra et al
[45]
Tunisia, 1996-1997 ≥ 19 yr 
(7860)





IFG: Impaired fasting glucose according to specified glucose range; FPG: Fasting plasma glucose; IGT: Impaired glucose tolerance (using World Health 
Organization definition, glucose ≥ 7.8 but < 11.1 mmol/L, 2 h after 75 gm oral glucose load); CI: Confidence interval; NA: Not available; A1c: Hemoglobin 
A1c.
Reports from Palestine, Iran, and Lebanon showed that a positive family history of 
T2D raised the risk by 1.6, 1.8, and 3.4 times, respectively[28,52,53]. Moreover, despite 
a higher prevalence of obesity in North America and Europe, MENA has a compar-
atively higher prevalence of diabetes, suggesting the presence of a genetic predis-
position to glucose intolerance.
Genome wide association studies have yielded several single nucleotide 
polymorphisms that appear to be associated with the development of diabetes. A 
recent meta-analysis reported that, for people in the MENA area, 71 single nucleotide 
polymorphisms in 32 genes increased the risk of T2D by 24%-69%[7]. There was a 
strong association with single nucleotide polymorphisms in the TCF7L2 (in 9 
countries) and CDKAL1 genes (in 4 countries), in addition to a variety of other loci, 
including ADIPOQ, FTO, MC4R. COL8A1, KCNQ1, ALX4, and HNF1. TCF7L2 was the 
most widely reported gene in the region, in countries that include Palestine[54], 
Lebanon[55], UAE[56], Egypt[57], Qatar[58], and Tunisia[59]. In the Lebanese 
population, associations with T2D have been found with variants of the COL8A1, 
KCNQ1, ALX4, and HNF1 genes[60]. The high rate of consanguinity reported for the 
MENA region, varying from 30% and up to 60%[8], likely further enhances the genetic 
susceptibility observed.
Transition in nutrition
In addition to the genetic predisposition, a worldwide transition to unhealthy diets 
and reduction in physical activity[61] plays a role in the development of obesity and 
diabetes. Diets have shifted to a higher consumption of calories, processed food, and 
animal fat, and a lower intake of fiber, fruits, and vegetables. In particular, the MENA 
area has experienced a rapid rate of modernization and urbanization over the past 
decades. An analysis of food availability and consumption by Mehio Sibai et al[62] 
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showed a gradual and significant rise in daily caloric, protein, and fat intake between 
1969-1971 and 2002-2004. It is estimated that the energy supply during that period rose 
from 2200 up to 2930 kilocalorie per day. In parallel, there was an increase in sugar 
intake and a reduction in the intake of fruits and vegetables. In Saudi Arabia, a recent 
study of people aged 35-70 years showed that 34% of participants reported an 
unhealthy diet, with a higher rate in younger individuals and those living in urban 
areas[63]. Similarly, a review paper from Lebanon found a rising trend of increased 
energy consumption from fat and animal product in the population, with a reduction 
in carbohydrate and cereal intake[64]. Another study from Lebanon found that 
consuming minimally processed food such as fruits, vegetables, legumes, breads, and 
cheeses was less likely to be associated with the metabolic syndrome (odds ratio = 
0.18, 95%CI: 0.04-0.77) and hyperglycemia (odds ratio = 0.25, 95%CI: 0.07-0.98) 
compared to the consumption of highly processed food such as fast foods, snacks, 
meat, nuts, sweets, and liquor[65].
Physical inactivity
With the rapid worldwide modernization and advancement in technology, a reduction 
in the rate of physical activity has occurred. In the MENA region, all countries have 
demonstrated an increase in physical inactivity, with a higher prevalence among 
females compared to males. Figure 3 shows the prevalence of physical inactivity in 
MENA countries subdivided by gender. Insufficient physical activity was defined as 
the percentage of the population aged above 18 years who are not performing at least 
150 min/wk of moderate-intensity physical activity or its equivalent[66]. There was a 
very high prevalence of insufficient physical activity in the high income Gulf countries 
with a prevalence ranging from 33%-67%, possibly because of a shift from manual 
labor/high physical activity jobs to occupations that are more sedentary in the services 
sector[67]. A study in Saudi Arabia found that more than 90% of surveyed individuals 
had an inadequate level of physical activity[68]. In contrast, that prevalence was under 
30% for Jordan, Morocco, and Tunisia. Females were consistently less active compared 
to males, possibly due to prevailing local customs in conservative countries where 
women may not spend as much time outside the home or in public places and may not 
frequent exercise facilities.
Obesity
Because of the adoption of unhealthy dietary habits and food choices, and the 
significant reduction in physical activity, the prevalence of obesity has been steadily 
increasing worldwide including in the MENA region. It is well-known that obesity is a 
significant risk factor for diabetes, with many studies showing a correlation between 
BMI and the incidence of diabetes[69].
Data from the WHO risk surveillance program has shown a significant rise in the 
rate of obesity across all countries. The countries most affected are the high-income 
Gulf countries, in addition to Egypt, Libya, Lebanon, and Iraq with rates exceeding 
30%. In contrast, Afghanistan, Pakistan, and Yemen boasted a relatively low 
prevalence, ranging from 5% to 17%. However, all countries suffered a rise in obesity 
prevalence between 2000 and 2016, ranging from 30%-100% (Figure 4). Interestingly, 
females were disproportionately more affected than males, with a prevalence that is 
comparatively 1.5-fold to 2.0-fold higher. Specifically, the prevalence of female obesity 
exceeded 40% in some Gulf countries (Saudi Arabia, Kuwait, Qatar, and UAE), in 
addition to Egypt and Jordan[70] (Figure 5).
COMPLICATIONS OF DIABETES
Mortality
NCDs account for around 70% of deaths worldwide[70]. In 2019, diabetes was the 
ninth leading cause of death with around 1.8 million directly attributed to hyper-
glycemia[71]. In addition, CVD, which is the leading cause of death and commonly a 
chronic complication of diabetes[72], claimed during the same year around 9 million 
lives[71]. Since 2019 and up until January 2021, the coronavirus disease 2019 (COVID-
19) pandemic had already surpassed world diabetes mortality with over 2 million 
deaths; however, diabetes was again an important risk factor for mortality or the 
development of severe COVID-19 infection[73].
Regionally, the MENA region scores the worst in terms of hyperglycemia-related 
mortality with an age-standardized mortality rate per 100000 (ASM) of 139.6 in 2016, 
followed by Southeast Asia, which has an ASM of 115.3 and in contrast to Europe with 
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Figure 3 Prevalence (%) of insufficient physical activity among adults aged 18+ year in 2016 (age-standardized estimate)[1].
Figure 4 Prevalence (%) of obesity by country among adults aged 18 years or older, defined as body mass index ≥ 30 kg/m2 (age-
standardized estimate) in 2000 and 2016[70].
an ASM of 55.7 and the Americas with an ASM of 72.6[74].
Focusing on the MENA region, there seems to be a pattern of lower ASM mortality 
from NCDs (diabetes, CVD, cancer, and chronic obstructive pulmonary disease) for 
some HIC of the Gulf and for the North African countries. Thus, in 2016, the ASMs for 
Oman, Qatar, Bahrain, and UAE were 404.6, 425.5, 430.1, and 460, respectively; 
similarly, for the North African countries of Algeria, Tunisia, and Morocco, they were 
430.7, 460.6, and 483.9, respectively. In contrast, in low/middle low-income countries, 
ASM was 681.0 for Pakistan, 805.3 for Afghanistan, and 819.7 for Yemen, per 100000
[75]. The ASM from NCDs for the MENA countries as well as the absolute number of 
deaths from diabetes or from CVD are presented Table 3. In addition to the apparently 
higher mortality in middle-income countries and low-income countries, the largest 
proportion of diabetes-related deaths occur among individuals under 60 years of age, 
with loss of productive years, adding to the socioeconomic burden of diabetes[2]. The 
finding of lower mortality for the HIC is consistent with recent world data[76,77].
Even if not leading to premature death, diabetes causes significant morbidity with 
disability, lower productivity, and quality of life. The MENA region again has the 
highest rate of disability-adjusted life years caused by diabetes[77].
Macrovascular complications
Having diabetes essentially increases the risk of having a major adverse vascular event 
defined as nonfatal myocardial infarction, stroke, heart failure, and/or cardiovascular 
death by 2-3-fold after adjusting for age, sex, and smoking status[72,76,78]. We could 
not find any large cohort studies nor national data on the above hard outcomes even 
from countries with a high prevalence of T2D who have a national diabetes registry 
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Table 3 Mortality from high glucose and cardiovascular disease extracted from the World Health Organization country profile data site 
for 2016[75]
2016 Total population (million)
Age-standardized mortality rate 











32527000 805.3 7056 2.17 51244 15.75
Algeria (MIC) 39667000 430.7 8390 2.12 69173 17.44
Bahrain (HIC) 1377000 430.1 404 2.93 775 5.63
Egypt (MIC) 91508000 711.8 17851 1.95 245904 26.87
Iran (MIC) 79109000 532.5 14842 1.88 160823 20.33
Iraq (MIC) 36423000 604.5 7279 2.00 51593 14.16
Jordan (MIC) 7595000 542.4 2347 3.09 13384 17.62
Kuwait (HIC) 3892000 541.4 326 0.84 4552 17.62
Lebanon (MIC) 5851000 516.4 1886 3.22 17814 30.45
Libya (MIC) 6278000 567.0 1292 2.06 11638 18.54
Morocco (MIC) 34378000 483.9 10645 3.10 69457 20.20
Oman (HIC) 4491000 404.6 903 2.01 4047 9.01
Pakistan (MIC) 189000000 681 44666 2.36 411569 21.78
Qatar (HIC) 2235000 425.5 359 1.60 1054 4.72
Saudi Arabia 
(HIC)
31540000 508.5 3737 1.18 42440 13.46
Syria (MIC) 18502000 594.7 1322 0.71 37885 20.48
Tunisia (MIC) 11254000 460.6 3523 3.13 31987 28.42
UAE (HIC) 9157000 460 707 0.77 5970 6.52
Yemen (MIC) 26832000 819.7 3854 1.44 56793 21.17
NCD: Noncommunicable diseases; CVD: Cardiovascular disease; LIC: Low income countries; MIC: Middle income countries; HIC: High income countries.
and/or have a relatively well-funded health care system[79]. The heterogeneity of the 
MENA population, the presence or absence of risk factors, and the inconsistent 
definition of outcomes makes comparisons between individual regions challenging. 
However, a recent study of 143567 adults with diabetes aged 35-70 years from 21 
countries around the world, including 5 countries from the MENA (Saudi Arabia, 
UAE, Iran, Palestine, and Pakistan) and followed for 9 years found an absolute 
incidence of major CVD among people with diabetes of 8.3; 9.2; and 10.3 per 1000 
person-years in HIC, middle-income countries, and low-income countries, 
respectively, as compared to 3.4; 4.9; and 5.3 per 1000 person-years in people without 
diabetes, respectively[76].
Specific to the MENA, the Tehran Lipid Study sampled 1198 adults aged ≥ 30 years 
with T2D and followed them for a median of 10 years. It reported a 23.4% and 14.3% 
cardiovascular and all-cause mortality, respectively. More than half of the mortality 
was due to cardiovascular events. Risk factors for death were male gender, smoking, 
and hypertension[80]. In a sample of 1308 adults with T2D recruited from primary 
care centers in Palestine, the prevalence of self-reported CVD was 12.2%[81]. The 
prevalence for CVD for Iran[4,80] and Palestine[82] is shown in Table 4.
On the other hand, risk factors for CVD, such as hypertension, dyslipidemia, 
smoking, physical inactivity, and obesity, are well documented through the 
implementation of the STEPS program by the WHO for most countries[17]. As an 
example, the prevalence of raised blood pressure (systolic blood pressure ≥ 140 and 
diastolic blood pressure ≥ 90 mmHg) was 26.3% for the EMR, which is the second 
highest in the world, with no gender predilection. It ranged from a low of 16.2% in 
Oman to as high as 25.0% in Pakistan. Similarly, the habit of smoking was high in this 
population, with a large gender difference, with 36.3% of men being active smokers 
(third highest in the world) vs 2.9% of women[17]. Of more concern is that a 
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Setting Duration of diabetes (yr)
Method of 
assessment Prevalence %




2000 (50.0) Diabetes Foot 
Clinic
11.7 ± 8.3 Physical exam 8.7
Al-Rubeaan et al
[89], 2015
Saudi Arabia 62681 (52.4) Saudi National 
Diabetes Registry
13.3 ± 8.1 Chart review 2.1
Yazdanpanah et al
[92], 2018
Iran (Ahfaz) 605 (42.8) Diabetes Clinic 9.2 ± 7.1 Physical exam 6.4
AlAyed et al[93], 
2017
Jordan 1000 (48.2) Diabetes Clinic 57.1% ≥ 5 Physical exam 5.3
Peripheral 
vascular disease
Akram et al[90], 
2011
Pakistan 830 (49.0) Outpatient Clinic 8.1 ± 6.2 low ABI; 
.4 ± 6.4 normal 
ABI
ABI below 0.9 31.6
Coronary artery 
disease
Saeedi et al[4], 2020 Iran 
(Kurdistan)
400 (18.0) Diabetes Clinic 14.6 ± 4.1 Angiography or 
physician




Palestine 1308 (35.9) Primary Care 
Centers
7.1 ± 6.3 Questionnaire 12.2 (myocardial 
infarction)
Afsharian et al[80], 
2016
Iran (Tehran) 1198 (42.1) Community-based NA Physician 
assessment
23.4
ABI: Ankle brachial index; NA: Not available; CABG: Coronary artery bypass grafting.
Figure 5 Prevalence (%) of obesity by country among male and female adults aged 18 years or older. Obesity defined as body mass index ≥ 30 
kg/m2 (age-standardized estimate) in 2000 and 2016[70].
substantial proportion of youth (aged 13-15 years) smoke cigarettes, reaching 10% in 
Qatar and 35% in the West Bank (Palestine)[82]. Additionally, the habit of waterpipe 
smoking is highly prevalent among youth in predominantly Arabic-speaking countries 
of the MENA region, with waterpipe exceeding cigarette smoking[82]. The prevalence 
of hypercholesterolemia (total cholesterol level ≥ 5.2 mmol/L) was 36.8% in the EMR
[70], which is comparable to the world prevalence. However, there is a higher predis-
position to the atherogenic dyslipidemias in this region, with an elevated prevalence of 
low high-density lipoprotein-cholesterol and familial hypercholesterolemia[83,84].
Given that the prevalence of CVD risk factors in the MENA region is high, it would 
be desirable to develop a predictive model adapted to its population. One such CVD 
predictive tool used 1314 Omani adults to develop it and another 405 individuals for 
validating it; that population sample was followed prospectively for 6 years and 
confirmed a 9% incidence of CV events[85].
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Diabetic foot ulcers
Diabetic foot ulcers (DFU) are a consequence of neuropathy and/or peripheral 
vascular disease. The lifetime risk for a person with diabetes to develop a DFU is 15%-
25%, and the global prevalence is 3%-8%[86]. In a systematic review of DFU involving 
Arabic speaking countries, a total of 9 studies were reviewed, representing 16512 
participants recruited from outpatient clinics. The prevalence of DFU was available for 
the following countries: Saudi Arabia (8.5%), Egypt (3.6%), Jordan (4.6%), Bahrain 
(5.9%), and Iraq (2.7%)[87]. A clinic-based study of 2000 adults with T2D in Alexandria 
(Egypt) found that 8.7% had DFU[88]. In a retrospective review of 62675 patients in 
Saudi Arabia, the prevalence of DFU was 2.05%, with an additional 1.06% suffering 
amputations[89].
Risk factors for DFU were a longer diabetes duration, male gender, higher BMI, the 
presence of an abnormal ankle-brachial index[90], and sensory neuropathy[88,91,92]. 
Prevalence of amputations varied from 1% to 2%[91,93]. Among 840 patients with 
diabetes in the Saudi National Diabetes Registry, the risk of mortality rose with DFU 
and increased further in the presence of lower extremity amputation, with a 
standardized mortality ratio of 4.39 and 7.21, respectively[94].
Microvascular complications
Most studies reporting on microvascular complications from the MENA region are 
either clinic or hospital based. However, some countries, like Saudi Arabia, possess a 
national diabetes registry, and others such as Iran have large cohorts followed longit-
udinally, like the Tehran Lipid Cohort. Among the three microvascular complications 
of diabetes namely nephropathy, neuropathy, and retinopathy, the latter is the most 
documented and studied.
Retinopathy
The overall global prevalence of DR is 34.6%, including 7.0% proliferative DR and 
6.8% clinically significant macular edema[95]. It is the most common cause of 
blindness in adults worldwide including the MENA region. The overall prevalence of 
DR in the MENA countries ranges from 12.6% to 37.8%, with proliferative DR ranging 
from 2.3% to 10.6%[96-99].
In a nationwide study of 50464 Saudi adults with T2D from the Saudi National 
Diabetes Registry, the prevalence of DR was 19.7%, with 10.6% proliferative and 5.7% 
clinically significant macular edema[100]. In a hospital-based study of 1325 adults with 
T2D from Egypt, the prevalence of DR was 20.5%[101]. In a clinic-based survey of 1308 
Palestinian adults with T2D, the prevalence of DR using nonmydriatic images was 
21.8%[81]. In a cross-sectional Tunisian clinic-based study of 2320 adults, the 
prevalence of DR was 26.3%, out of whom 3.4% had proliferative DR and 4.2% had 
clinically significant macular edema[102]. In a systematic review in Iran which 
included 17079 individuals, the overall prevalence of DR was 37.8%, with wide 
variability among regions[103]. The prevalence of DR for the various countries is 
shown in Table 5.
Importantly, retinopathy was found even among newly diagnosed adults with T2D. 
In Pakistan, DR was present at diagnosis in 15.9% of 958 adults with T2D[99]. 
Similarly, in Jordan, DR was documented in 7.9% of 127 adults with T2D within 6 mo 
of diagnosis[104]. Finally, in a retrospective chart review from Lebanon of 484 adults 
with T2D, DR was present in 26.6% at first ophthalmologic examination[105].
The elevated prevalence of DR at diagnosis is in line with the high proportion 
(44.7%) of undiagnosed diabetes for the MENA region[2]. It is likely that there is a 
latency period from onset of diabetes to time of its diagnosis, during which damage to 
the retina is taking place. In support of this theory is that duration of diabetes has been 
consistently reported as a risk factor for DR across most studies[96,100,101]. Even after 
being diagnosed, regular ophthalmologic check-ups were uncommon. This was 
evidenced in a community-based screening campaign of 2205 adults with mostly T2D, 
for whom only one third had regular retinal exams by an ophthalmologist[96]. 
Similarly, in Egypt, out of 1325 adults with long-standing diabetes, 82% were not 
aware of the need to do retinal checks[101]. Other risk factors for DR were poor 
glycemic control, older age, higher BMI, hypertension, smoking, the use of insulin, and 
the presence of other microvascular complications[97,98,100].
Nephropathy
Studies assessing nephropathy are more heterogeneous, with some reporting on 
albuminuria, others on glomerular filtration rate, and very few on end-stage renal 
disease. A global study evaluating the impact of diabetes on disability-adjusted life 
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Table 5 Select studies reporting on microvascular complications of diabetes in the Middle East and North Africa region





Retinopathy Al-Rubeaan et al
[89], 2015
Saudi Arabia 50464 (56.0) Saudi National 
Diabetes Registry
13.4 ± 8.2 Chart review 19.7 (10.6 PDR)
Macky et al[101], 
2011
Egypt 1325 (28.5) Hospital-based 48% for 5-15 Slit lamp 20.5 (2.3 PDR)
Jammal et al
[104], 2013
Jordan 127 (63.8) Clinic-based Newly 
diagnosed
Slit lamp 7.9
Uddin et al[99], 
2018





Palestine 1308 (35.9) Primary Care 
Centers
7.1 ± 6.3 Digital retinal 
photo
21.8
Elshafei et al[97], 
2011
Qatar 540 (360/540) Community-based 12.9 ± 9.1 Slit lamp 23.5
Heydari et al
[98], 2012
Iran 1022 (40.2) Clinic-based 11.2 ± 8.2 DR; 
5.8 ± 5.4 no DR
Slit lamp 23.6
Arej et al[96], 
2019





Tunis 2320 (39.8) Hospital-based 7.6 Slit lamp 26.3 (3.4 PDR)
Nephropathy Al-Rubeaan et al
[107], 2018
Saudi Arabia 54670 (51.2) Saudi National 
Diabetes Registry
13.6 ± 8.1 ACR and GFR 10.8 (1.2 micro; 8.1 
macro; 1.5 ESRD)
Uddin et al[99], 
2018










550 (54.7); Age 
above 35 yr
Diabetes Clinic 8.9 ± 6.8 ACR 34.6 (5.8 macro)
Ali and Al Lami
[109], 2016
Iraq 224 (58.9) Diabetes Clinic 23.2 % ≥ 9 ACR (2 out of 3) 16.1
Neuropathy Khedr et al[22], 
2016
Egypt (Qena) 9303 (51.1); 837 
with diabetes





517 (32.0) Primary Health 
Clinic
9.0 ± 7.5 Monofilament test 38.2
Chahbi et al
[115], 2018





Libya 450 (50.2) Diabetes Clinic 15.1± 7.1 Diabetic 
Neuropathy Score
42.2 (s-LANSS ≥ 12 
pain)
Kiani et al[113], 
2013
Iran 521 (NR) Diabetes Clinic 9.2 ± 7.4 NSS and NDS 49.3
NR: Not recorded; MNSI: Michigan neuropathy screening instrument, ENG: Electroneurogram; PDR: Proliferative diabetic retinopathy; ACR: Albumin to 
creatinine ratio; S-LANSS: Leeds assessment of neuropathic symptoms and signs; NSS: Neuropathy symptom score; NDS: Neuropathy disability score; DR: 
Diabetic retinopathy; GFR: Glomerular filtration rate; ESRD: End-stage renal disease.
years in the EMR reported more than doubling of diabetes-related chronic kidney 
disease between 1990 and 2005[77]. This doubling was not only due to the increased 
prevalence of diabetes or aging but also due to more obesity, salt intake, and 
uncontrolled blood pressure[77]. In a national study from Libya, the estimated 
prevalence of end-stage renal disease was 624 per million. The major cause was 
diabetes, followed by hypertension[106].
The prevalence of microalbuminuria ranged from 10.8% in Saudi Arabia[107] to 
34.6% in Palestine[108], with Iraq[109], Iran[110], and Pakistan[99] at 16.1%, 20.6%, and 
24.0%, respectively. Macroalbuminuria constitutes about 15% of the reported 
albuminuria. The prevalence of nephropathy from selected studies is shown in Table 5.
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Risk factors for albuminuria were elevated blood pressure, high BMI, duration of 
disease, hyperglycemia, and the presence of diabetes complications[107,109,110].
Neuropathy
Diabetic peripheral neuropathy is the most common complication of diabetes; at least 
50% of individuals with diabetes will develop it to some extent[111]. Neuropathy 
negatively affects quality of life and constitutes a major risk for DFUs. Despite its high 
prevalence, studies on neuropathy are heterogeneous in terms of the populations 
studied, the setting (clinic or community-based), and the testing procedure used 
(questionnaire, monofilament test, or electroneurogram). Similarly, the prevalence in 
the MENA region varies from 18.5% (Egypt)[22] to 42.2% (Libya)[112] and 49% (Iran)
[113], using a standardized scoring system. Using a simple monofilament test, the 
prevalence was 38% in an outpatient clinic in Palestine[114]. Painful neuropathy is less 
common and was 15.4% in a cross-sectional study of 300 adults in Morocco[115]. 
Increasing age, duration of disease, high BMI, poor glycemic control, smoking, and 
low educational level were predisposing factors[112,113]. Peripheral neuropathy is 
overall more common in men, whereas painful neuropathy was more common in 
women[115].
DIABETES IN CHILDREN AND ADOLESCENTS
Whereas diabetes in children and adolescents used to be mostly limited to T1D, there 
has been, over the last two decades, an increasing proportion developing T2D globally
[15]. Moreover, in some countries, such as Japan, T2D in children and adolescents has 
become more prevalent than T1D[2]. Because of the earlier onset of the disease, 
affected children are expected to have a higher prevalence of complications in 
adulthood compared to others with adult-onset T2D within the same age group[17]. 
Furthermore, T2D starting at an early age would adversely affect productivity at its 
peak, raise the healthcare costs, and increase morbidity and mortality[15].
We could not find recent data about the overall prevalence of T2D in children and 
adolescents in the MENA region; however, data from specific countries reflect an 
increasing incidence and prevalence of T2D in this age group. In Kuwait, for instance, 
the incidence rate of T2D between 2011 and 2013 among children and adolescents, 
aged ≤ 14 years, was 2.56 per 100000 per year[116]. In Qatar, there were no registered 
cases of T2D among children and adolescents before 2008. Afterwards, the incidence of 
T2D increased from 1.16 per 100000 in 2012 to 2.72 per 100000 in 2016[117]. In Saudi 
Arabia, a nationwide survey conducted over years 2007-2009 found that 0.45% of the 
adolescents aged less than 18 years were known to have diabetes; out of which, 0.07% 
was T2D (n = 17). Moreover, the prevalence of newly diagnosed IFG and diabetes 
(both types) were 6.1% and 4.3%, respectively[118]. In Riyadh, T2D in the age group 7-
17 years was found to be more common than T1D with a prevalence of 4.5%[33].
Moving to Iran, from 2001 to 2011, 1% of adolescents developed prediabetes and 
T2D each year[119]. The study found that males were 1.28 times more likely to 
develop prediabetes and T2D than females, which differs from an American study for 
diabetes in youth, the SEARCH study, that found the prevalence to be higher among 
females. This lower prevalence among Iranian females could be attributed to the ethnic 
differences and to how prediabetes was defined. This study included IFG only in its 
definition of prediabetes, which is, in contrast to IGT, a more common phenotype in 
males than females, thus contributing to the higher prediabetes prevalence among 
Iranian males[119]. As for Lebanon, a cross-sectional study was conducted in 2007 
among students aged 11-18 years at three private schools in an urban area. It found 
that 10.5% of the students had IFG, and 3.5% had diabetes. Among overweight and 
obese individuals, the risk of developing prediabetes or diabetes was 4.93 and 2.85 
times higher, respectively. The diagnostic criteria used did not differentiate between 
T1D and T2D; however, since the majority of those diagnosed with prediabetes and 
diabetes were overweight or obese, they were likely insulin resistant. Therefore, T2D is 
on the differential and should be confirmed for such a patient profile[120].
Modifiable risk factors
Obesity: One of the most important risk factors for T2D in adolescents is obesity. In 
the UAE, the prevalence of prediabetes and T2D among overweight and obese public 
school students, aged 11-17 years, were 5.4% and 0.87%, respectively[121]. 
Furthermore, 100% of all the children and adolescents with T2D in Qatar were either 
overweight or obese[117], and 23.35% of Saudi adolescents with diagnosed diabetes 
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were obese[118].
Obesity presents a challenging health problem in the MENA region, where the rates 
of obesity have been increasing rapidly among children and adolescents at a faster rate 
than adults[122]. According to the WHO, the crude prevalence of obesity among 
children and adolescents in the region ranged from 2.4% in Afghanistan to 22.8% in 
Kuwait in 2016[123].
In Lebanon, two cross-sectional studies were conducted in 1997 and 2009 using the 
WHO definition for obesity in children and adolescents as age and sex specific scores + 
2. The prevalence of obesity in the age group 6-19 years increased from 7.3% in 1997 to 
10.9% in 2009[124]. Moreover, obesity was more common in boys (10.1%) than in girls 
(4.2%) in private schools, whereas there was no gender difference in public schools 
(6.7% and 6.0% for boys and girls, respectively)[120]. In Pakistan, recent data from 
Hazara city showed that the prevalence of obesity among school students was 4.78%, 
and similarly to Lebanon the prevalence was higher in private compared to public 
schools[125].
Physical inactivity: The Global School-based Student Health Surveys found that 
physical inactivity, defined as less than 60 min activity per day on 5 or more days in 
the past 7 d, was very high among children and adolescents in MENA countries and 
was higher in girls compared to boys. The prevalence was 65.4% in Lebanon, 72.5% in 
the UAE, 80% in Iraq, and more than 80% in many MENA countries, reaching as high 
as 90.6% in Egypt. The high sedentary lifestyle rates can be partly due to lack of 
encouragement of physical activities from parents, teachers, and friends, while 
favoring spending more time on other tasks such as their education[126].
Non modifiable risk factors
Family history: Along with obesity and physical inactivity, the genetic predisposition 
and family history present significant risk factors for T2D in adolescents[127]. The risk 
of abnormal glycemic status among Emirati school students was 1.9 times higher 
among those who have first degree relatives with diabetes; moreover, it was found 
that more than half of Emirati students with prediabetes and all those with T2D had a 
positive family history of diabetes[121]; the same applies to Qatari adolescents with 
T2D[117].
Other non-modifiable risk factors are low birth weight, maternal diabetes during 
pregnancy, and the postmenarchal phase in females[126]. During puberty, there is a 
physiological 30% increase in insulin resistance that, in the presence of other risk 
factors, can precipitate T2D; thus, the onset of T2D in youth is earlier in girls than boys 
and manifests itself usually during the second decade of life.
In summary, the youth of the MENA region are particularly vulnerable to 
developing T2D because of a culmination of risk factors. Multilevel interventions are 
needed to be able to effectively reverse this wave.
The management of T2D in children and adolescents presents a real challenge due 
to the poor adherence to the management recommendations of this age group and the 
difficulty in reversing obesity[128]; moreover, many of the young T2D patients are 
asymptomatic. Thus, it is important to screen those at risk. The ADA guidelines 
recommend screening children starting age 10 years or earlier (in case of an earlier 
onset of puberty) for all obese or overweight children if they have one additional risk 
factor[128]. The management for T2D in children and adolescents should include 
reduction of 7%-10% of the excess weight, physical activity for at least 60 min/d, and a 
healthy balanced diet rich in nutrients. Moreover, optimal blood pressure control and 
annual screening for neuropathy and retinopathy are crucial to prevent and manage 
complications[128]. All of these should be accompanied by educating patients and 
their parents about self-management including self-monitoring of blood glucose. We 
could not identify any studies from the MENA on the management of T2D in this age 
group.
CHALLENGES
In brief, the MENA region has the highest prevalence of T2D, and the rates continue to 
rise steeply. Furthermore, it has one of the highest diabetes related disability-adjusted 
life years and mortality rates from NCDs. Modifiable risk factors for both diabetes and 
its complications are highly prevalent in this population and extend to the pediatric 
and adolescent age group.
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To address and reverse this situation is a daunting yet unavoidable task. Emerging 
factors add to the challenge, such as the increasing pollution level and environmental 
degradation, the high level of geopolitical instability, and most recently the COVID-19 
pandemic. The latter two have had a direct impact on diabetes care.
Refugees and displaced people
In 2021, the United Nations High Commissioner Report indicated that there are 17.4 
million refugees, internally displaced or physically constrained people in the MENA 
region. These are predominantly from Syria, Iraq, Yemen, and Libya[129]. They 
constitute about 3% of the MENA population, and 18% of the global population of 
concern. During the year 2000, 24 million Yemeni people depended on assistance. In 
parallel, the rates of extreme poverty have doubled in the region, from 3.8% to 7.2% 
between 2015 and 2018, and are likely to rise further due to the financial strain of the 
COVID-19 pandemic[130]. Furthermore, in 2020 the MENA region was deemed the 
‘least peaceful’ area in the world with its many armed conflicts and/or political 
instability[131].
The above factors negatively influence NCDs in general and diabetes in particular. 
They also weaken the public healthcare system. The optimal management of diabetes 
requires a patient-centered approach with continuity of care[132]. Instead, in an 
unstable setting, the care is typically fragmented and interrupted, and the health of 
refugees and of displaced civilians is very likely to suffer. Unfortunately, very few 
national studies address the health status of refugees, so the prevalence of diabetes 
complications may be underestimated.
One such study was conducted in Lebanon on both the Lebanese population and 
Syrian refugees, as part of the STEPwise approach[133]. Out of 1899 Lebanese and 
2134 Syrian adults aged 18-69 years, 51.2% of Lebanese had three or more 
cardiovascular risk factors vs 59.8% of Syrians. A 2014 survey by the United Nations 
High Commissioner Report found that close to 15% of adult Syrian refugees had at 
least one chronic condition, with 16% of those having diabetes, half of whom reported 
difficulties accessing health services[13]. With social instability and lack of security in 
parts of other MENA countries, it is expected that similar conditions may be prevalent
[14]. The situation is likely to be complicated by poverty, food insecurity, poor 
nutrition, and inability to access health care. A concerted effort by the international 
community and governmental health agencies is needed to assist vulnerable people 
and provide them with access to medical care.
COVID-19 and diabetes
The COVID-19 pandemic has stressed the healthcare system and highlighted the need 
for a stronger infrastructure. Resources of all countries, even those that are relatively 
affluent, have been strained. National health systems should invest in interventions 
that aim at improving diabetes care. This is of paramount importance, in view of the 
data that shows a worse prognosis and an increased risk of complications and 
mortality for patients with diabetes hospitalized with COVID-19 infections[134]. A 
recent report from Qatar suggested that patients with diabetes hospitalized with 
COVID-19 infection had more severe clinical manifestations of pneumonia and acute 
respiratory distress syndrome and longer duration of hospitalization, intensive care 
stay, and mechanical ventilation[135]. Another study from Saudi Arabia reported that 
during the COVID-19 lockdown, patients with diabetes had reduced compliance with 
their medications and with healthy lifestyle habits[136]. Moreover, it is likely that 
many patients with diabetes have had a disrupted outpatient follow-up care due to 




There is ample evidence that diabetes can be prevented or delayed and its complic-
ations significantly reduced[137]. A recent editorial emphasized that worldwide 
implementation of diabetes prevention measures is an urgent matter[138]. Our review 
of T2D in the MENA region provides an opportunity to identify gaps and potential 
remedies for diabetes-related public health problems.
More accurate and complete data collection is needed for individual countries 
because available data is frequently scarce, outdated, relies on historical estimates, or 
is extrapolated from other similar countries. Without reliable data, the magnitude of 
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the problem can be under/overestimated, and areas of need cannot be properly 
identified.
In addition, the socioeconomic disparities in the care of diabetes need to be 
addressed because a lower socioeconomic background frequently emerged as a risk 
factor for diabetes and for complications. Strategies need to be put in place to address 
this issue, with interventions that are evidence-based, cost effective, and designed to 
improve access to care.
Another worrisome finding is the gender difference manifesting as a higher 
prevalence of obesity and physical inactivity among women compared to men. It calls 
for an investigation of potential reasons and for implementation of remedial solutions, 
especially that gestational diabetes carries the risk of generational transmission of 
metabolic syndrome[139].
Furthermore, there is an urgent need to introduce programs that educate about 
healthy nutrition choices and promote healthy habits. Proper monitoring of 
implementation of planned interventions followed by evaluation of their impact is 
mandatory. Strategies to promote and encourage physical activity are needed, whether 
through urban planning with introduction of sidewalks and walking trails or through 
building exercise facilities that are accessible and affordable.
Policies are needed to label food items with their nutritional and caloric content. 
Educational programs need to be introduced at the school, community, and workplace 
levels, with emphasis on adapting them to the local cultures and norms. To be 
effective, educational programs need to be culturally sensitive and tailored to the 
functional health literacy of the local population[140]. The national media and 
advertising industry need to be involved in educating the public, in partnership with 
the national health system. Telehealth may play an important role in terms of raising 
awareness and providing better access to care[141], especially in view of the geopol-
itical instability and the COVID-19 pandemic.
In addition, there is a need to promote a public health awareness at the level of 
primary health care providers for screening and managing diabetes and associated 
metabolic comorbidities. There is evidence to suggest that quality of care is not 
optimal[142]. Educational activities need not only address risk factors for diabetes 
such as obesity and unhealthy lifestyles but also how to manage diabetes and its 
potential complications and how to implement preventive measures to avoid complic-
ations, such as regular eye and foot exams and kidney function tests.
The prevention and management of diabetes should be the perfect prototype of 
‘health into all policies.’ In 2013, the WHO announced the Global Action Plan for the 
Prevention and Control of Non-Communicable Diseases 2013-2020 aimed at curbing 
the rise in obesity and diabetes. However, it is evident that not enough has been done 
so far to achieve this goal, and efforts have fallen short of the magnitude of the 
problem. Therefore, national strategies need to be put in place to address noncommu-
nicable diseases in general and diabetes in particular, with an emphasis not only on 
planning but also on implementation. In 2021, the WHO is launching the WHO Global 
Diabetes Compact, which would enable countries (especially low and middle income) 
to prevent diabetes by addressing risk factors and help these countries develop their 
capabilities in identifying and treating people with diabetes[143]. Such programs are 
urgently needed in the MENA region.
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